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Abstract
Introduction: The main cause of anastomotic leakage (AL) is tissue hypoxia, which results from impaired perfusion of the pedicle
stomach graft after esophageal reconstruction. Clinical judgment is unreliable in determining graft perfusion. Therefore, an objective,
validated, and reproducible method is urgently needed. Near infrared ﬂuorescence perfusion imaging using indocyanine green (ICG)
is an emerging and promising modality. This study’s objectives are to evaluate the feasibility of quantiﬁcation of ICG angiography
(ICGA) to assess graft perfusion and to validate ICGA by comparison with hemodynamic parameters, blood and tissue expression of
hypoxia-induced markers, and tissue mitochondrial respiration rates. And, second, to evaluate its ability to predict AL in patients after
minimally invasive esophagectomy (MIE).
Methods:Patients (N=70) with resectable esophageal cancer will be recruited for standard MIE. ICGA will be performed after graft
creation and thoracic pull-up. Dynamic digital images will be obtained starting after intravenous bolus administration of ICG. The
resulting images will be subjected to curve analysis and to compartmental analysis based on the adiabatic approximation to tissue
homogeneity kinetic model. The calculated perfusion parameters will be compared to intraoperative hemodynamic data to evaluate
the effects of patient hemodynamics. To verify whether graft perfusion represents tissue oxygenation, ICGA perfusion parameters will
be compared with systemic and serosa lactate from the stomach graft. In addition, perfusion parameters will be compared to tissue
expression of hypoxia-related markers and mitochondrial chain respiratory rate. Finally, the ability of functional, histological, and
cellular perfusion and oxygenation parameters to predict AL and postoperative morbidity in general will be evaluated using the
appropriate univariate and multivariate statistical analyses.
Discussion: The results of this project may lead to a novel, reproducible, and minimally invasive method to objectively assess
perioperative anastomotic perfusion during MIE, potentially reducing the incidence of AL and its associated severe morbidity and
mortality.
Trial registration: Clinicaltrials.gov registration number is NCT03587532. The study was approved by the ethical committee of
the Ghent University, Belgium (B670201836427).
Abbreviations: AATH = adiabatic approximation to tissue homogeneity, AL = anastomotic leakage, EC = esophageal cancer,
ECCG = Esophagectomy Complications Consensus Group, ICG = indocyanine green, ICGA = indocyanine green angiography, MIE
= minimally invasive esophagectomy, NIR = near infrared, NIRF = near infrared ﬂuorescence, PiCCO = Pulse index Continuous
Cardiac Output, ROC = receiver operating characteristics curve, ROI = region of interest.
Keywords: anastomotic leakage, esophagectomy, indocyanine green angiography, near-infrared ﬂuorescence imaging,
oxygenation, perfusion, stomach graft
Funding: This research project is funded by “Kom op tegen Kanker” (Stand up to Cancer), the Flemish cancer society which has no role in the design of the study, nor
in the collection, analysis, or interpretation of the data or in the manuscripts’ writing.
The authors have no conﬂicts of interest to disclose.
a Department of Gastrointestinal Surgery, b Department of Electronics and Information Systems, c Department of Aging Physiology and Molecular Evolution,
d Department of Pathology, e Department of Anaesthesiology, Ghent University Hospital/Ghent University, Ghent, Belgium.
∗
Correspondence: Elke Van Daele, Department of Gastrointestinal Surgery, University Hospital 2K12 IC, Corneel Heymanslaan 10, B-900 Ghent, Belgium
(e-mail: elke.vandaele@uzgent.be).
Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Medicine (2018) 97:38(e12073)
Received: 31 July 2018 / Accepted: 3 August 2018
http://dx.doi.org/10.1097/MD.0000000000012073
Study Protocol Clinical Trial Medicine®
OPEN
1
1. Introduction
1.1. Esophagectomy
Over the past 2 decades the incidence of adenocarcinoma of the
esophagus is rapidly increasing.[1] Despite extensive changes in
therapeutic modalities surgical resection remains the cornerstone
in therapy for curable esophageal cancer (EC). After the
esophagectomy, the stomach is most commonly used to restore
continuity of the upper gastro intestinal tract. However,
anastomotic sites are prone to serious complications such as
leakage, ﬁstulas, bleeding, and strictures. Anastomotic leakage
(AL) remains one of the main causes of postoperative morbidity
and mortality in digestive surgery. The reported leakage
incidence after esophagectomy ranges from 5% to up to
20%.[2–6] The leak-associated mortality is 18% to 40%
compared with an overall in-hospital mortality of 4% to
6%.[2,7,8] Several risk factors for AL have been identiﬁed.[2–11]
The perfusion of the anastomosis is generally considered to be an
important predictor for anastomotic integrity. During surgery the
clinical judgment of the surgeon determines the anastomotic
region’s viability based on subjective parameters as color and
vessel pulsation. A good noninvasive method to objectively assess
viability and perfusion of the anastomotic site could help the
surgeon to reliable decide the appropriate anastomotic region.
1.2. Perfusion assessment methods
Several methods have been tested to intraoperatively evaluate
graft’s perfusion, such as Laser speckle contrast imaging, gastric
tonometry, Doppler ﬂowmetry, spectroscopy, and angiogra-
phy.[12–15] None of them have been widely accepted due to
different reasons. Most of these methods could differentiate well-
perfused from hypoperfused tissue but failed to give quantitative
physiological information on vascular perfusion. Angiography is
a widely used easy, intraoperative tool to provide structural
information on vascularization. Quantifying angiography would
combine the advantages of a structural imaging with the
necessary info needed from a functional perfusion analysis.
1.3. NIRF imaging with ICG
Indocyanine green angiography (ICGA) is an emerging medical
imagingmodality requiring a ﬂuorescence-imaging agent that can
be excited at near infrared (NIR) wavelengths. Penetrating NIR
light excites a near-infrared ﬂuorescence (NIRF) agent generating
ﬂuorescence that can be captured by adapted cameras to create a
2D image of tissue deposition of the NIRF imaging agent.
Indocyanine green (ICG) is a clinically used NIRF agent with
excellent safety records. Its absorption maximum around 760 to
780nm, its conﬁnement to the vascular compartment (due to
binding with plasma proteins), its low toxicity, and its rapid and
almost exclusive biliary excretion has added to the rapid Food
and Drug Administration approval for clinical use in 1956. ICG
has been used intraoperative in neurosurgical, coronary,
vascular, and reconstructive surgeries as a nonspeciﬁc blood
vascular imaging agent to assess organ perfusion.[16]
1.4. ICGA-guided esophageal surgery
Objective, in-depth assessment of tissue perfusion using NIR
imaging during creation of the esophagogastric anastomosis in
EC surgery has not been previously reported. Most studies
aiming to measure intraoperative tissue perfusion during surgery
have used invasive probes or methods that sample only a small
tissue volume. Several pilot studies were published that report
promising results of NIRF-based perfusion imaging during EC
surgery.[17–20] However, these were feasibility studies, and did
not encompass any attempts to calculate physiologically relevant
parameters, quantify perfusion, or validate imaging ﬁndings by
comparison with a criterion standard.[17–24]
2. Methods and analysis
2.1. Study design
This is a prospective, single-center, in vivo, observational study
on 70 patients undergoing minimally invasive esophagectomy
(MIE) with a pedicle gastric graft reconstruction in the
department of digestive surgery at the University Hospital of
Ghent. ICGA images perfusion measurements, blood samples,
and biopsies will be obtained after creation of the gastric tube and
before the esophagogastric anastomosis. Dynamic ICGA digital
images will be obtained and subjected to curve analysis and to
compartmental analysis based on the adiabatic approximation to
tissue homogeneity (AATH) kinetic model. The calculated
imaging based perfusion assessment of the stomach graft will
be compared to intraoperative hemodynamic data and validated
using tissue, serum, and cellular hallmarks of hypoperfusion and
hypoxia. Finally, the ability of functional, histological, and
cellular perfusion and oxygenation parameters to predict AL and
postoperative morbidity in general will be evaluated using the
appropriate univariate and multivariate statistical analyses.
The methodology was developed according to the strengthen-
ing the reporting of observational studies in epidemiology
(STROBE) and the statement for reporting studies of diagnostic
accuracy (STARD) guidelines. The protocol was written based on
the Standard protocol items for clinical trials (SPIRIT) checklist.
2.2. Study objectives and endpoints
The primary endpoint will be to determine an ICGA-based cutoff
point to predict AL and graft necrosis after esophageal
reconstructive surgery. This cutoff value will be an ICGA
ﬂuorescent intensity time measurement expressed in seconds.
Secondary endpoints are the following:
 The evaluation of ICGA as a quantitative perfusion imaging
modality during gastric tube reconstruction. First, intensity
over time curves will be analyzed in the regions of interest to
generate quantitative values for maximal ﬂuorescence intensity
(Imax), inﬂow time (Tinﬂow), and outﬂow time (Toutﬂow).
Second, a kinetic modeling analysis of the time-varying ICG
concentration images will be performed, based on a tracer
kinetic model that was developed to measure tissue blood ﬂow
and vascular permeability.
 The validation of ICGA imaging by comparing the quantitative
data:
 To continuous perioperative hemodynamic measurements
from a Pulse index Continuous Cardiac Output (PiCCO)
catheter.
 To biological markers of hypoxia and ischemia: systemic and
capillary lactate levels (measured in systemic and serosal blood
samples) and mitochondrial chain respiratory rates (measured
on tissue biopsies).
 And to histopathological ischemic markers of hypoxia and
ischemia.
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 Patient outcome in terms of AL and necrosis deﬁned by the
Esophagectomy Complications Consensus Group (ECCG)
classiﬁcation and identiﬁed by clinical and radiological
methods. Based on a receiver operating curve we hope to
determine a cut-off value for the prediction of gastric graft
malperfusion.
 Product-related toxicity.
 Surgery-related endpoints: number of crossover patients:
perioperative change of anastomotic site based on ICG ﬁndings,
perioperative blood loss, and perioperative adverse events.
 Incidence of minor and major adverse events up to 30 days
postoperatively classiﬁed by the Clavien-Dindo score and
based on the ECCG international consensus for complications
associated with esophagectomy.[25]
 Intensive care unit and in hospital stay and ﬁnally incidence of
stricture up to 1 year postoperatively.
2.3. Study population
All nonmetastatic EC patients aged ≥18 years and scheduled for
elective MIE with an intrathoracic stapled esophagogastric
anastomosis will be screened for inclusion and exclusion criteria.
Once potentially eligible, study procedures will be explained to
the candidate and participation will be offered. Subjects willing to
participate must be physically and mentally ﬁt for surgery, and
need to sign an informed consent after a consent process and
before any study-related procedures may take place. Surgery
must be within 90 days of signing the informed consent. Patients
will be excluded in case of known hypersensitivity to ICG. Female
patients who are pregnant or nursing, patients participating in
other studies involving investigational drugs or devices, and
patients with documented use of Avastin (bevacizumab) or other
anti-vascular endothelial growth factor agents within 30 days
before surgery. During surgery exclusion criteria will be
reanalyzed and patients will be excluded in case of intraoperative
ﬁndings that may preclude conduct of the study procedures, when
anastomosis is performed differently than the standard of care
and in case of excessive bleeding (>500mL) before anastomosis.
2.4. Sample size
For the sample size we focused on the accuracy with which the
ICGA quantitative parameters will be able to predict AL. For an
alpha=0.05 and a power of 0.80, a total sample size of 54
patients is required to be able to show a statistically signiﬁcant
difference of the area under the curve in a receiver operating
characteristic curve (ROC), provided that a leak rate of 16% is
observed. Including a 10% drop out or lost to follow-up, we
intent to include 70 patients.
2.5. Study interventions
2.5.1. Surgical procedure. A standard MIE will be performed
using the Ivor Lewis technique (intrathoracic stapled esophago-
gastric anastomosis). Three regions of interest (ROIs) will be
marked on the stomach graft with a suture (Fig. 1):
ROI 1: well perfused control region: 2 to 3cm proximal to the
pylorus
ROI 2: clinically identiﬁed anastomotic site: study region
ROI 3: ischemic control region: in the proximal (excluded)
stomach
2.5.2. ICG-based NIR perfusion imaging. Imaging will be
performed twice: 30 minutes after the creation of the stomach
graft (in the abdomen), and immediately before creation of the
esophagogastric anastomosis (in the right thorax). A dose of 0.5
mg/kg of ICG (ICG-Pulsion, Pulsion Medical Systems, Munich,
Germany) will be injected as an intravenous bolus. Images will be
recorded starting immediately before injection until 3 minutes
afterwards. Video data will be obtained with a charge-coupled
device camera ﬁtted with a light-emitting diode emitting at a
wavelength of 760nm, and the appropriate ﬁlters to detect NIR
ﬂuorescence (Visera elite II, Olympus Medical System Corp,
Tokyo, Japan). The ﬂuorescence signals are sent to a digital video
processor to be displayed on a TV monitor in real time (Fig. 2).
2.5.3. Hemodynamic evaluation. Advanced continuous hemo-
dynamic monitoring during surgery will be performed using a
PiCCO (Pulsion Medical Systems) catheter integrating a wide
array of both static and dynamic data through a combination of
transcardiopulmonary thermodilution and pulse contour analy-
sis. All patients will be monitored through a central venous line in
the right or left jugular or subclavian vein and a Pulsioncath
thermodilution catheter in left or right femoral artery.
2.5.4. Biological and pathological markers of ischemia.
Blood and tissue samples will be collected at the 3 ROIs
immediately after the 2 deﬁnedmoments of ICGA. In order not to
harm the conduit, no extra tissue will be resected compared to the
standard Ivor Lewis procedure. Pathological specimen and tissue
samples will be analyzed in the Department of Pathology at the
University of Ghent. Biological specimens will be analyzed at the
surgical research lab of the University of Ghent. Samples will be
fully identiﬁed and stored at the research laboratory until the end
of the study, thereafter they will be destroyed.
The ﬁrst biological marker is systemic and local capillary
lactate: systemic lactate will be measured on a blood gas sample
during surgery at the beginning of the surgical procedure and at
the 2 deﬁned imaging moments. Tissue capillary lactate will be
measured with a handheld lactate analyzer (EDGE Analyzer,
Apex Biotechnology, Taiwan) at the same moments on blood
samples obtained by a serosa puncture at the 3 ROIs.[23,24,26]
Figure 1. The regions of interest during gastric tube construction.
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The second marker of ischemia is the mitochondrial
respiratory chain assessment: Mitochondrial activity will be
measured on full-thickness stomach biopsies at the previously
marked ROIs. Samples will be placed in a 2-mL water jacketed
oxygraphic cell equipped with a Clark type electrode (Oxygraph-
2k, Ororboros Instruments, Innsbruck, Austria). Basal oxygen
consumption and maximal tissue respiration rates at 37°C in the
presence of a saturating amount of adenosine diphosphate as
phosphate acceptor will be measured.[23,24,26]
Finally, pathological analyseswill be performed on the biopsies
at the 3 ROIs after they will be buffered in formalin and stained
with hematoxylin and eosin. A semiquantitative scoring based on
the presence of ﬁbroblasts, polynuclear neutrophils, lympho-
cytes, andmacrophages will be used to evaluate the severity of the
inﬂammation. Further planned analyses (in addition to standard
histology: TNM 7, Mandard regression score) include ﬂuores-
cence in situ hybridization of the MDM2 gene and immunohis-
tochemistry analyses of ischemia-associated proteins HIF-1a,
MDM2, CDK4, and p16.[23,24,26–30]
2.6. Follow-up and data collection and management
2.6.1. Follow-up. Primary follow-up will be up to 30 days with
clinical evaluations daily and radiological evaluations based on
the standard of care of the department, and outpatient clinic
follow-up visits at 30 to 60 days postoperatively. Extended
follow-up will be foreseen until 1 year postoperatively for
stricture.
2.6.2. Data collection. All data will be retrieved from the
electronic medical database and collected on Clinical Research
File sheets. Three-minute long video ﬁles of the ICGA will be
stored on a computer and analyzed with AMIDE ROI software
(http://amide.sourceforge.net).
2.6.3. Image analysis. Image analysis will be performed using
curve analysis and compartmental modeling. First, intensity over
time curves will be analyzed in the ROIs to generate quantitative
values for maximal ﬂuorescence intensity (Imax), inﬂow time
(Tinﬂow), and outﬂow time (Toutﬂow). Second, a kinetic modeling
analysis of the time-varying ICG concentration images will be
performed. This analysis will be based on a tracer kinetic model
that was developed to measure tissue blood ﬂow and vascular
permeability and that has been used previously to assess vascular
parameters in a tumor mode and in the brain.[31,32] This complex
model (AATH)will be applied on the extracted maps of perfusion
and vascular permeability from the video frame rate images
acquired after a bolus injection of ICG. The arterial input
function of ICG, which is required for modeling, will be extracted
from the images by identifying the gastric artery. This analytic
work will be done in collaboration with the Imaging Division,
Lawson Health Research Institute, London, Ontario.
2.6.4. Data analysis. The quantitative imaging data will then be
correlated with chemical and pathological markers of ischemia
(Capillary lactate levels, mitochondrial chain respiratory rates,
histopathological assessment, and immunohistochemical
markers of ischemia) and with postoperative morbidity and
mortality, including radiological or clinical AL (recorded and
scored using the Clavien-Dindo scale). Based on a receiver
operating curve we hope to determine a cut-off value for the
prediction of gastric graft malperfusion, based on the Youden
index.
2.7. Statistical analysis
Study data will be collected in an excel data collection sheet, in
which descriptive statistics can be provided for all measured
parameters. Quantitative data are expressed as mean and/or
median with standard deviation, interquartile range, or min-max
range. Data will be analyzed using standard statistical software
(SPSS version 22 for windows, SPSS Inc, Chicago, IL). An ROC
curve for sensitivity and speciﬁcity for leakage as binary classiﬁer
will be constructed. From this curve, the Youden index will be
used to calculate a best-ﬁt cut-off point. Statistical analysis using
chi-square test, Fisher exact test, and Mann-Whitney U test will
be performed whenever needed. A P value <0.05 is considered
statistically signiﬁcant.
2.8. Ethics
This study will be conducted in accordance with the declaration
of Helsinki and in agreement with the guidelines and principles of
Good clinical practice. All patients will receive oral and written
information before obtaining written consent in case of approval.
This ﬁnal version of the protocol was approved on 12/6/2018 by
the medical ethical committee of Ghent University Hospital (EC/
2018/0671), registered by the Belgian research committee
(B670201836427), and submitted to the clinicaltrials.gov
database (NCT03587532). Enrolment will start on September
1, 2018.
3. Discussion
Esophageal anastomoses are fragile and prone to leakage, which
is associated with signiﬁcant morbidity, mortality, and impaired
quality of life. The perfusion of the anastomosis is generally
considered to be an important predictor for anastomotic
integrity. During surgery the clinical judgment of the surgeon
determines the anastomotic region based on subjective param-
eters. A good noninvasive method to objectively assess viability
and both macro- and microvascular perfusion of the anastomotic
site could help the surgeon to reliably decide the appropriate
anastomotic region. Such a test needs to be easily available, cost
effective, objective, and reproducible. NIRF imaging with ICG
might combine all these advantages but is not yet calibrated nor
validated. The proposed clinical study would be the ﬁrst to use
NIRF dynamic images to calculate physiologically relevant
parameters (blood ﬂow, blood volume, vascular leakage) and
Figure 2. Expected ICGA perfusion through the gastric tube. ICGA=
indocyanine green angiography.
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generate pseudocolor coded parametric maps using advanced
curve analysis and compartmental modeling (AATHmodel).[26,31]
In addition, this study would be the ﬁrst to validate imaging-based
perfusion assessment of the stomach graft using tissue, serum, and
cellular hallmarks of hypoperfusion and hypoxia. Data from this
study will result in quantiﬁcation of ICGA images, evaluate its
potential to assess graft perfusion, and analyze its impact on AL
after MIE for EC. The results of this project may allow to predict,
and therefore avoid, AL after EC surgery. This may, in turn,
prevent the morbidity and mortality associated with AL. Also, the
results might contribute to a better understanding of gastric graft
perfusion and oxygen supply in EC surgery.
In conclusion, this study will produce quantitative perfusion-
related measurements for an objective ICGA assessment of tissue
perfusion during surgery. The insights gained and the methods
developed during this project may also beneﬁt patients
undergoing other types of cancer surgery (rectum, pancreas
. . . ) in which anastomotic tissue viability is of critical
importance.
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